Ors had a higher percentage of DDR mutations than Leptomycin B Protocol variety I tumors (70.59 vs. 28.85 , p 0.001, chi-squared test). The advancedBiomedicines 2021, 9,9 ofstage patients had greater percentage of DDR mutations than the early-stage individuals (57.28 vs. 27.54 , p 0.001, chi-squared test). Recurring individuals had a greater percentage of DDR mutations than those with no recurrence (53.92 vs. 32.86 , p = 0.006, chi-squared test). Individuals who died of EOC had a larger percentage of DDR mutations than living sufferers (59.21 vs. 34.38 , p = 0.001, chi-squared test). EOC sufferers without DDR gene mutation had longer progression-free survival (PFS) (p = 0.0072, log-rank test, Figure 2A) and all round survival (OS) (p = 0.022, log-rank test, Figure 2B) than those with 1 DDR or 2 DDR mutations. In serous carcinoma, individuals with or without the need of DDR mutations had related PFS (p = 0.56, log-rank test, Figure 2C). Patients with two DDR mutations had a trend of much better OS than these with 1 mutation or none, but it was not statistically considerable (p = 0.47, log-rank test, Figure 2D). In endometrioid carcinoma, sufferers with 2 DDR gene mutations had shorter PFS (p = 0.0035, log-rank test, Figure 2E) and OS (p = 0.015, log-rank test, Figure 2F) than those with 1 mutation or none. In clear cell carcinoma, patients with two DDR gene mutations had substantially shorter PFS (p = 0.0056, log-rank test, Figure 2G) and OS (p = 0.0046, log-rank test, Figure 2H) than these with 1 DDR mutation or none. Tumor recurrence with CCR gene mutation (HR: 1.68 (1.12.50), p = 0.011), 1 DDR gene mutation (HR: 1.71 (1.12.60), p = 0.013), endometrioid carcinoma (HR: 0.17 (0.08.37), p 0.001), variety II tumor (HR: two.69 (1.81.00), p 0.001), advanced-stage carcinoma (HR: 5.29 (3.16.85), p 0.001), high-grade tumor (HR: 5.57 (2.263.70), p 0.001) and optimal debulking surgery (HR: 0.28 (0.18.41), p 0.001) had been substantial within the univariate Cox regression model (Table five). Advanced-stage carcinoma (HR: three.08 (1.63.80), p = 0.001) and optimal debulking surgery (HR: 0.51 (0.32.80), p = 0.004) had been important prognostic variables in the multivariate evaluation. Cancer-related death with TLS gene mutation (HR: 33.76 (three.9589.00), p = 0.001), 1 DDR gene mutation (HR: 1.96 (1.20.20), p = 0.007), endometrioid carcinoma (HR: 0.12 (0.04.38), p 0.001), sort II tumor (HR: 1.88 (1.19.96), p = 0.007), advanced-stage carcinoma (HR: six.84 (three.284.25), p 0.001), high-grade tumor (HR: 17.97 (two.5029.29), p = 0.004) and optimal debulking surgery (HR: 0.26 (0.16.41), p 0.001) have been significant inside the univariate Cox regression model. Variety II tumor (HR: 0.35 (0.20.60), p 0.001), TLS gene mutation (HR: 9.57 (1.084.83), p = 0.042), advanced-stage carcinoma (HR: 4.82 (2.091.09), p 0.001) and optimal debulking surgery (HR: 0.38 (0.22.64), p 0.001) have been essential prognostic aspects inside the multivariate analysis.Biomedicines 2021, 9,ten ofTable 4. The correlation of DDR gene mutations with clinical parameters within the epithelial ovarian cancer sufferers. Genes OSA Total HR Wild variety Mutation p worth NHEJ Wild sort Mutation p worth MMR Wild form Mutation p value BER Wild variety Mutation p value 160 93.02 12 6.98 65 94.20 4 5.80 37 94.87 two five.13 58 90.63 6 9.38 0.631 96 92.31 8 7.69 64 94.12 4 five.88 0.649 65 94.20 four 5.80 95 92.23 8 7.77 0.619 27 93.ten 2 six.90 133 93.01 10 6.99 0.985 66 94.29 four five.71 94 92.16 eight 7.84 0.59 91 94.79 five 5.21 69 90.79 7 9.21 0.306 161 93.60 11 six.40 67 97.ten two 2.90 33 84.62 six 15.38 61.